Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Branch II Clear all
Completed Phase 1Phase 2 Interventional Results available

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT04432597
View directory record Official record
Conditions
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer, Cervical Cancer
Interventions
PRGN-2009, M7824, EKG, CT Scan, Brain MRI, Biopsy
Biological · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Imaginal Exposure II Study: In-Vivo

NCT03934697
View directory record Official record
Conditions
Eating Disorder, Anorexia Nervosa, Bulimia Nervosa, Exposure
Interventions
imaginal exposure therapy
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 19, 2026, 11:59 AM EDT
Active, not recruiting Phase 2 Interventional

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448
View directory record Official record
Conditions
Lung Cancer
Interventions
Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
La Jolla, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Not yet recruiting Not applicable Interventional

OCM™ Treatment With Routine Care in Venous Leg Ulcers Compared to Routine Care Treatment Alone.

NCT07754526
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
Omeza OCM™ Wound Matrix, Routine Care
Device · Procedure
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups

NCT06090643
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Consultation, Educational Intervention, Electronic Health Record Review, Fecal Immunochemical Test, Feedback, Health Education, Support Education Activity, Text Message-Based Navigation Intervention
Other · Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
9,745 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Resistance Training and Protein Supplementation for Prostate Cancer Survivors

NCT01909440
View directory record Official record
Conditions
Prostate Cancer
Interventions
exercise intervention, nutritional supplementation, quality-of-life assessment, questionnaire administration, pharmacological study, laboratory biomarker analysis
Behavioral · Dietary Supplement · Procedure + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
50 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

NCT02023697
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 19, 2026, 11:59 AM EDT
Not listed Phase 3 Interventional

Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas

NCT00278278
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
cisplatin, etoposide, ifosfamide, lomustine, methotrexate, prednisone, vincristine sulfate
Drug
Lead sponsor
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Other
Eligibility
3 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

NCT00627276
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 19, 2026, 11:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

QuadraMune(TM) for Prevention of COVID-19

NCT04421391
View directory record Official record
Conditions
Covid19, Coronavirus, SARS-CoV 2
Interventions
QuadraMune(TM)
Dietary Supplement
Lead sponsor
Therapeutic Solutions International
Industry
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 19, 2026, 11:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

NCT04584255
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
8
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

NCT02144675
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
choline magnesium trisalicylate, idarubicin, cytarabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937
View directory record Official record
Conditions
Multiple Myeloma, Primary Amyloidosis
Interventions
Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

NCT02208037
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
Interventions
Tacrolimus (ARM with Methotrexate), Tacrolimus (ARM with MMF and Cyclophosphamide), Methotrexate (ARM with Maraviroc), Methotrexate (ARM with Bortezomib), Maraviroc, Bortezomib, Mycophenolate mofetil, Cyclophosphamide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
30
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 19, 2026, 11:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02443077
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Interventions
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
280
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors

NCT06682039
View directory record Official record
Conditions
Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
Interventions
Internet-Based Intervention, Interview, Questionnaire Administration, Text Message-Based Navigation Intervention
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
15 Years to 29 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

NCT01418001
View directory record Official record
Conditions
Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Interventions
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer

NCT05746429
View directory record Official record
Conditions
Bone Sarcoma, Childhood Cancer
Interventions
Cognitive Behavior Therapy, Transcranial Direct Current Stimulation, Placebo Administration, Questionnaire Administration, Interview
Behavioral · Device · Drug + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

NCT03090737
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 19, 2026, 11:59 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

NCT00556075
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex 25 mg, Placebo, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 19, 2026, 11:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03493945
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
Interventions
M7824, N-803, MVA-BN-Brachyury, FPV-Brachyury, Epacadostat, Acetaminophen, Ibuprofen, Naproxen, Benadryl, EKG, Bone scan, CT chest, abdomen and pelvis, MRI
Biological · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 19, 2026, 11:59 AM EDT
Active, not recruiting Phase 2 Interventional

Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer

NCT01203839
View directory record Official record
Conditions
Breast Cancer
Interventions
multiple beams utilizing either intensity-modulated or 3D-conformal techniques
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 11:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

NCT04225039
View directory record Official record
Conditions
Glioblastoma
Interventions
INCMGA00012, INCAGN01876, SRS, Brain surgery
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 19, 2026, 11:59 AM EDT